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SYSTEM DISEASES OF BONE 
Discussion Leader: 
DR. GEORGE NICHOLS, JR. 
NICHOLS: There are three reasons for including a discussion on 
“System Diseases of Bone” in a symposium of this type. 
The first reason is that clinical bone disease occurs or will occur 
in the majority of us by the time we leave this planet. Osteoporosis, 
for example, can be shown to be present-even though it may be 
asymptomatic-in close to 50 percent of all women over 60 and is 
almost equally common in men, although it appears rather late in life. 
Since the origins and treatment of these diseases are largely unknown, 
there are good reasons for attacking these problems from a purely 
medical point of view. The clinicians badly need the help of their 
colleagues in basic science in finding the new answers which they 
seek. 
A second reason is that this discussion is of use to those of us who 
are basic scientists if it brings to our attention the natural experiment 
provided by disease. Such experiments have told us more than once 
what questions to ask. Sometimes we have found the answer by turn- 
ing to man, sometimes by turning back to the animal with new insight. 
Later I will present some examples which will perhaps illustrate this 
point. 
Third, there are reasons, well illustrated by the discussions of 
earlier sessions, to think that we are at the beginning of a new era in 
our understanding of bone and its diseases. Those of us who are 
physicians will remember that bone disease was first described in 
terms of gross structural disturbance. This began, probably, as far 
back as the Egyptians and has gone on ever since. More recently, 
bone disease was studied in terms of mineral metabolism because it 
was easier to correlate the nutritional aspects of mineral metabolism 
with bone disease than anything else that could be measured at that 
time. So we went through an era dominated by Albright, in which 
external balances of calcium, phosphorus, and nitrogen were cor- 
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related with various forms of bone disease. We are now reaching 
a point where we can start to think about bone disease in yet another 
way, in terms of cell or tissue biology; it is to this aspect that I will 
address my remarks. 
Bone disease, approached at the level of cell biology, can be thought 
about in quite simple terms. There are actually only two sets of‘ 
processes going on: accretion and resorption. Once the details of 
these processes are known, including their initiation and control, it 
is possible to describe the phenomena of embryogenesis, of growth 
or remodeling, and perhaps of calcium and phosphorus homeostasis in 
terms of these two systems. By the same token, we will be able to 
describe bone disease in terms of the derangement of these two proc- 
esses and the balance between them. 
I will speak almost entirely about matrix, partly because one can 
deal with only one thing at a time and partly because matrix appears 
as the primary material which determines form; the chemical charac- 
teristics of the matrix, once they have been laid down, serve to attract 
the necessary mineral to provide rigidity. Although mineral metab- 
olism may affect the processes of resorption and secretion of matrix 
in some situations, in general it tends to be a follower rather than a 
leader. 
The first step in developing these ideas is to list those things we wish 
to know in order to look at bone disease. We need to understand the 
nature and the sequence of the steps involved in biosynthesis of matrix, 
the substrate requirements and rate of each. Similarly, we must know 
how resorption takes place and what steps in the process are rate 
limiting. Finally, we will need to know what controls exist for each 
overall process and how they work. This category includes not 
only such things as substrate availability and hormones but also a 
host of other factors, which may well be the most impoTtant of all, 
such as responses to local stimuli. This information will provide 
answers to such intriguing questions as “What tells bone cells that a 
fracture has occurred and callus formation is needed?” 
Figure 85, which I prepared for another symposium a year ago, 
summarizes the state of our knowledge about bone-cell metabolic 
systems and provides us with ideas of where controls might be applied. 
The information on which this diagram is based has been provided 
by a number of sources, some dealing with bone and some with other 
connective tissues. As can be seen, we have quite a bit of biochemical 
information about bone cells. There are transport systems for glucose 
and amino acids (shown by the circle at the left of the cell) which get 
the raw materials in. We know that amino acids are concentrated in 
the cell either by a transport system or by synthesis from glucose as a 
precursor. It has also been shown that these amino acids are activated, 
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BONE CELL 
FIGURE 85. Bone-cell metabolic systems. 
tied onto their appropriate transfer RNA’s, and assembled, presumably 
by a ribosomal mechanism, into collagen which is then stored in vesicles 
and finally extruded into the extracellular phase. The rate of each of 
these steps and of the overall process can be measured. A second 
arrow emerging from the protein synthetic scheme, and leading to 
lysosomes and collagenase, has been included to remind us that these 
factors are present and involved in resorption. These collagenase- 
containing bodies have been shown as storage vesicles which also 
extrude their contents extracellularly to indicate that the collagenase 
must work outside rather than inside the cell. Whether two separate 
ribosomal paths exist (in the same or different cells) for these two 
processes is not known, but the presumption can be made that the 
information for the biosynthesis of each flows from the nucleus via 
messenger RNA. 
Energy to drive these systems is needed; so ATP is formed by a 
breakdown of glucose, partly by glycolysis and production of lactic 
acid and partly by an oxygen utilizing system with the production of 
COz and, in this particular cell, the release of citric acid as well. The 
relation of this acid production to bone-mineral mobilization and hence 
resorption has been suggested so often that it need not be reviewed 
here. 
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One of the conveniences of this scheme is that it permits potential 
sites for control of rates of accretion and resorption to be seen at a 
glance. For example, the deposition of extracellular collagen could be 
controlled by such varied factors as change in transmission of nuclear 
information, availability of energy, availability of sdstrate,  variations 
in the biosynthesis of amino acids from glucose, or release of collagen 
from storage vacuoles. Similarly, resorption rate is clearly dependent 
on rates of acid production, biosynthesis of enzymes, and the mech- 
anisms for delivery of enzymes into the extracellular space. 
These thoughts, in turn, lead to a very simple classification for various 
bone diseases (table XIV). There are just three kinds of disturbances 
that can occur: (1) a defect in cellular machinery, (2) a deficiency in 
the availability of raw materials, or (3) a disturbance in the controls 
that regulate the rates of one or more steps; the latter disturbance 
can be subdivided into three categories: (a)  hormonal, (b) local, and 
(c) “informational.” This scheme with examples of diseases that, 
according to present information, fit into each category are shown 
in table XIV. Osteogenesis imperfecta, in which collagen synthesis 
seems to be deficient or deranged, appears to be a good example of 
a defect in cell machinery. Nutritional deficiency has been ilkstrated 
by osteomalacia, but scurvy could be cited equally well. The hor- 
monal example is obvious, bi t  perhaps the choices for the “local” 
and “informational” categories need some defense. Osteoporosis 
was picked for the former category because there are aberrations of 
the metabolic pattern in the bone cells in such patients, but so far 
no cause outside of the cells has been found for these changes. An- 
other example which might be even better would be “fracture.” It 
was omitted because it seemed a local rather than a systemic bone dis- 
ease. Myeloma has been used because it is a widespread diffuse 
tumor that often produces bone disease that, if our recent evidence 
can be believed, may well result from a redirection of cellular biosyn- 
thetic activity. 
TABLE XIV 
CLASSES OF BONE DISEASE 
Example 
(1) Defects of cellular machinery .............................. 
(2) Deficiency of substrates.. .......................... 
(3) Disturbance of controls: 
(a) Hormonal ............................................. 
(b) Local ................................................... 
(c) “Informational” I . .  
Osteogenesis imperfecta 
Osteomalacia 
Hyperparathyroidism 
Osteoporosis of disuse 
Multiple myeloma 
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RAISZ: Why not put myeloma under (2)? 
NICHOLS: Because we have some experimental data which suggest 
that it should not be. 
BUDY: What about genetic defects? Do you put them all under 
cellular machinery defects? 
NICHOLS: Yes, I have, Dr. Budy, on the basis that most genetic 
defects eventually turn out to be enzyme deficiencies. 
FREMONT-SMITH: That is information, is it not? 
NICHOLS: I put it where I did because I have recently obtained some 
experimental information suggesting that genetic defects are probably 
not nutritional. 
PRITCHARD: Where would an osteogenic sarcoma come into the 
system? 
NICHOLS: I am not sure, but at present I would put it with myeloma. 
PRITCHARD: What about infection with viruses and bacteria? 
NICHOLS: I do not know. Where should I put them? 
PRITCHARD: In nutrition? 
URIST: Make a special category for infection. 
FREMONT-SMITH: And have another one for miscellaneous. 
NICHOLS: One must have a scheme in mind to guide one’s work, 
and this is the scheme under which we have studied 103 patients with 
all sorts of diseases. In some instances, there are enough patients and 
the results are consistent enough for a pattern to be assigned to a 
disease; for example, hyperparathyroidism. Since we have already 
published these findings (ref. 152), I will not dwell on them. Instead, 
I would like to present some data on osteoporosis, in the hope that you 
will be able to help me understand what they mean; then I would like to 
go on to the skeletal response to fluoride. We will show an animal 
model, as well as some human data. Dr. Peck also has some informa- 
tion which l hope he will bring out (ref. 153) and thus move the discus- 
sion to the changes induced by multiple myeloma. 
Listed in table XV are bone metabolic data for 17 patients with 
osteoporosis and who range in age from 39 to 78 years (ref. 154). 
Three patients were treated with sodium fluoride for 1 year prior 
to biopsy, and one was studied before and after 1 year of sodium fluoride 
treatment. The metabolic data included in this table were derived 
from in vitro studies of biopsy samples and include measurements of 
several aspects of bone-cell function summarized in our hypothetical 
cell. The rate of collagen synthesis was measured in two ways: 
(1) from the incorporation of labeled proline, which reflects synthesis 
from preformed amino acids, and (2) from glucose, which measures 
amino acid as well as protein synthesis. Accumulation of label from 
these substrates in the cell fraction reflects a variety of cellular ac- 
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tivities. We now know (ref. 155) that proline label is to be found 
concentrated in the cell sap as the free amino acid, as well as incor- 
porated into collagen and constituent cellul~r moteins. While some 
proline label is probably present in metabolic intermediates as well, 
much more of the glucose label is to be found in such materials. 3s Cohn 
and Forscher (ref. 156) first showed. We also know that glucose label 
must be present in free amino acid (ref. 157), in nascent collagen, and 
in cell proteins as well. Thus, glucose label in cells reflects many 
functions and probably should be taken as an index of overall metabolic 
activity. Finally, energy metabolism is estimated in two ways: (1) by 
O2 uptake and (2) by lactate production, the latter perhaps being 
related to bone-mineral resorption as well. 
At the bottom of the table, the means of values derived from eight 
normal subjects together with their standard deviations are shown for 
comparison. While bone from eight normal subjects was studied, data 
in some categories were collected from as few as four. The combina- 
tion of the small number of subjects and of the considerable variability 
in metabolic activity that seems to occur from sample to sample resulted 
in standard deviations as large as 50 percent of the mean. Yet despite 
this, at least one and sometimes several of the metabolic variables 
measured was more than two standard deviations away from the 
normal mean in all but 3 of the 17 patients studied. Table XVI will 
make this clearer. 
BAUER: How about the normals? Were they normal in all respects? 
They need not be, you know. 
NICHOLS: That is perfectly true. Data for eight normals are shown. 
Since this table was prepared, we have done three additional normal 
subjects. 
If they are included in the means they are very similar, as are the 
standard deviations. The latter are a bit smaller, but not much. The 
total normal group now ranges in age from 17 to 43 years and includes 
five men and three women. All were patients hospitalized for surgery 
which involved the skeleton, but who did not have any evidence of 
systemic bone disease. Nor were they people with recent fractures; 
this is important, as we have since discovered. 
FREMONT-SMITH: Why is this important? 
NICHOLS: That they did not have fractures is important because 
the presence of a recent fracture, even at some site remote from the 
biopsy area, seems to stimulate bone metabolic activity. 
BAUER: It seemed, from table XV, that every osteoporoticindividual 
studied was abnormal, i.e., outside the normal range, in every one 
of the variables studied. How abnormal were the nonosteoporotic 
subjects? 
NICHOLS: This is a compilation of all the normal data available 
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at the time. The gaps occurred because of broken tubes, insufficient 
bone to measure everything in a given individual, and so forth. 
HEANEY: In which way were they abnormal? Were they just 
outside the standard deviation in both directions? 
NICHOLS: Yes, and this is what we are going to discuss in table XVI. 
MACDONALD: Are these biopsies? 
NICHOLS: Yes; the majority were taken from the iliac crest. 
HOWELL: How many grams of bone does it take for that battery 
of studies? 
TABLE XVI 
OXYGEN CONSUMPTION 
Sample no. 
32 ....................................... 
42 ....................................... 
44.. ..................................... 
48.. ..................................... 
29.. ..................................... 
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NICHOLS: When we started these studies we needed about 1Y2 
grams. Recently, we have refined our methods so that we can do 
most measurements with 300 milligrams. If collagenase activity 
is also measured, we need about 500 milligrams. There are some 
additional problems that arise when the sample size is very small. 
For example, the total cellularity of this tissue is quite low, so there 
is a risk of not having a representative sample of the several types of 
cells; the total number of cells is too small. At least this seems the 
best explanation for the increasing variation one gets as the sample 
size decreases. 
Faced with the kind of scattered data shown in table XV, the next 
step is to see whether clear patterns emerge when the patients are 
classified on the basis of one or another metabolic variable. The 
next three tables illustrate such possible classifications. 
Table XVI shows what happens when patients are grouped according 
to bone-cell oxygen consumption. Three groups can be distinguished 
with low, normal, or high values depending on whether their values 
fall within, below, or above two standard deviations on each side of 
the mean value found in samples from normal subjects. Although the 
majority fall within the normal range, four subjects with low rates of 
O2 uptake and four subjects with increased rates can be identified. 
However when the results of other metabolic studies are examined, 
no very consistent pattern is found. About all that can be said is that 
when O2 uptake is low, collagen biosynthesis is apt to be normal or 
low, while the label retained in cells is generally normal or (as in two 
cases) increased. In patients with normal bone-cell O2 uptake, other 
data also tend to fall in the normal range. What changes are present 
tend to be above the normal range; the same is true when O2 uptake 
is abnormally high. 
Clearly, this classification does not bring out any very well defined 
patterns of change. Similarly, classification based on rates of collagen 
biosynthesis from glucose (table XVII) or proline (table XVIII) fails 
to identify any clear-cut pattern of disturbed metabolism. Again, 
most of the patients fall into the normal category of each classification. 
When other classifications are tried, the results are equally disappoint- 
ing. Indeed, the only common denominators which appear are that 
cellular-label retention from both glucose and proline is either normal 
or high, even in people with normal or low rates of collagen synthesis 
from the same precursor. 
Incidentally, several of these patients had received sodium fluoride 
treatment for upward of a year at the time of biopsy. One patient was 
studied both before and after I year of treatment with 100 milligrams 
sodium fluoride by mouth each day. I t  was interesting that the meta- 
bolic patterns in these patients could not be distinguished from the 
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TABLE XVII 
COLLAGEN SYNTHESIS FROM GLUCOSE 
- 
- 
Sample no. 
n n + - 
n n + n 
32.. ...................................... 
42.. ...................................... 
30b.. ............................... 
35.. ...................................... 
40.. ...................................... 
46.. ...................................... 
50.. ...................................... 
53.. ...................................... 
71 ........................................ 
Normal 
High 
rest. Some changes did occur, however, in patient 30 (see table XV) 
during her year of treatment, a period over which she developed 
roentgenographic evidence of fluorosis of the skeleton. 
The question, of course, is “What do these data mean?” My answer 
at present is, unfortunately, ‘‘I do not know,” but perhaps you will be 
able to help me understand them. 
URIST: May we call for some questions now about what you have 
covered so far? 
NICHOLS: I was going to ask Dr. Heaney or Dr. Bauer to tell me 
how they would attack the problem from here. I find myself at a loss. 
HEANEY: Before you call for questions, I would say your statistics 
are unmanageable. There is nothing in your presentation that could 
not be accounted for by random chance; this is not to say that real - 
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the data. 
I am merely talking about interpreting 
NICHOLS: I have also come to this conclusion. 
RAISZ: I would like to ask about the problem of age. Your normds 
ranged from age 17 to 43 years, and I think the patients were all older 
except for one patient of 4 1. Was this a lady who had had her gonads 
removed? 
NICHOLS: urprisingly enough, it was a man. 
311-496 0-68-15 
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RAISZ: The question remains as to whether there is variability 
with age in these measurements. 
NICHOLS: We cannot entirely determine this. We suspect that 
very young people have a much faster bone metabolic rate; but we 
have relatively few data from children, and most of these are abnormal 
children, because it is very difficult to get a normal child’s bone in 
adequate quantity. The few samples that we have studied show 
variable higher ‘rates, sometimes as much as threefold or fourfold the 
adult normal as defined by these numbers. 
HOWELL: You refer to DNA as a standard of reference? 
NICHOLS: Yes; DNA. 
FREMONT-SMITH: What with automobile accidents and all, I should 
think you would have a lot of normal bone available, even from children. 
NICHOLS: The problem is that people are rarely autopsied until 
some hours after death, and by this time the tissue has deteriorated, 
unfortunately. 
FREMONT-SMITH: But people are operated on; amputations and all 
kinds of things are happening. There would seem to be a real oppor- 
tunity if one could alert a group of surgeons to the kinds of specimens 
you want and to what these specimens should be put into. 
HEANEY: I think, Dr. Fremont-Smith, it would be very important 
to work entirely with bone from exactly the same region. We have 
enough variability without taking a hit-and-miss sample from a leg here, 
a finger here, and a finger there. 
FREMONT-SMITH: There are quite a lot of legs, and I suspect one 
would have not four to seven normals but perhaps 40 or 50 normals in 
a few years. One of the situations evident here is that the sample of 
normals is completely inadequate to base anything on. I am sure a 
careful effort with accident cases coming into operation would provide 
at least a better sample of normals than Dr. Nichols has. 
NICHOLS: Obtaining good normal materials is indeed the most critical 
issue at this time. 
PECK: I would like to ask about the effect of anesthesia on the 
metabolism of surviving cells. 
NICHOLS: I do not know. 
PECK: Do you have any patients that were operated on under various 
types of anesthesia? 
NICHOLS: The biopsies were obtained under a variety of anesthesias, 
most of them general anesthesia. I have not examined the data in 
relation to the anesthetic agent; it should be done. 
BAUER: What, by definition, do you mean by “osteoporosis”? For 
those who do not work in this field, may I explain that therc are several 
current definitions of osteoporosis; whatever definition one chooses, it is 
Dr. Peck, did you have a question? 
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still difficult to distinguish between osteoporosis and nonosteoporosis. 
NICHOLS: This group was defined as follows; they had pain. 
BAUER: Where? 
NICHOLS: The patients had crushed vertebrae, as shown by roent- 
genographs. They had normal serum calcium and phosphorus. 
BAUER: My other question is “Have you done this kind of analysis 
on‘bone biopsies in experimental animals?” 
NICHOLS: We have data from rats, pigs, guinea pigs, and rabbits, 
but none from dogs or cows. 
BAUER: Even though you do not have too much normal material- 
(this is the same practically for whatever one tries to do in studies of 
disease-it is difficult to get normal materials), I am sure that the 
biochemical methods, or other methods, used are much more difficult 
to handle than the logistic problem of getting normals. When you 
compare the changes that you find in your few normals with those of 
the many nonnormals, are these comparisons in approximately the 
same range as those in your animal experiments? 
NICHOLS: The normal range appears, so far, to be wider in man 
than in animals, but I think this probably is a function largely of number 
of samples examined. 
ROBINSON: In the investigations of bone that you obtain at the time of 
surgery, there are apt to be, particularly in the osteoporotic individual, 
many other cell types in the whole bone specimen besides osteoblasts, 
osteoclasts, and osteocytes. Do you have any way of standardizing 
your sample so that you know how much actual bone tissue is in this 
specimen of whole bone? It appears that you have a DNA ratio per 
gram of wet weight, and a lot of the D N A  might be associated with 
cells that are not concerned directly with bone accretion, resorption, 
or maintenance. 
NICHOLS: This is basically the problem of marrow contamination, 
which is with us in all our work with animals as well as man. The 
answer to your question is not entirely adequate, but perhaps if I 
explain the details of our procedures you will see how we try to mini- 
mize the contamination with marrow and other nonbone cells. 
The biopsy, when taken, is chilled immediately in Krebs-Ringer 
buffer at 2” to 3” C and transported at that temperature in buffer to the 
laboratory; there it is carefully scraped free of soft tissue. Iliac crest 
samples, at least, are a mixture of a thick plate of cortical bone with 
trabecular bone attached. Both are finely minced with a bone rongeur 
and then shaken quite vigorously with cold buffer. By the way, Dr. 
Talmage tells me that this is the way he gets osteoclasts out. 
TALMAGE: Roughly. 
NICHOLS:- We use this technique to wash out cells that look like 
If washed three times, a piece of bone which marrow on smear. 
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was red is now pale pink or white and on histologic examination has 
lost most of its marrow elements. 
ROBINSON: And then you weigh that material? 
NICHOLS: Right. Then after incubation, the cell fraction is separated 
chemically. 
BAUER: Have you had an opportunity to compare your data obtained 
on biopsy material with data obtained on autopsy material; Le., from 
individuals who have been dead for 24 hours? 
NICHOLS: Actually, we have done only two post mortem samples, 
both traumatic. Neither showed much, if any. activity, as I recall. 
However, this was some time ago, and perhaps we should go back 
and try again. 
Paget’s disease is something we have yet to study. We have looked 
at the influence of fractures once, in a patient with osteogenesis imper- 
fecta. We have also examined isolated cases of other diseases. I 
showed you osteoporosis partly to see if somebody could help me find 
an interpretation of the data and partly because our findings indicate a 
completely polyglot group of cellular disturbances; this is important 
because osteoporosis is a polyglot disease. 
RAISZ: I do not believe that the complexity of your data rules out 
a simplistic theory of osteoporosis. Although this theory may not 
be correct, I would like to hear the reaction of this group to the pos- 
sibility that there is a single mechanism for the development of oste- 
oporosis. I think that the variations which you have observed could 
occur on the basis of the heterogeneity of the population of cells that 
we have been looking at. 
MACDONALD: Do those data not show that there is a need for a 
method that would establish whether the osteopenia is progressing or 
whether it is quiescent? Perhaps this distinction in these patients 
would simplify some of the comparisons that may bother you. Meth- 
ods of determining whether the osteoporosis is active or quiescent 
might open a new area for discussion. 
PECK: I think it would be very valuable, if feasible to obtain; the 
reproducibility of the observation in the same patient from day to day, 
week to week, and even month to month. 
NICHOLS: This is something we have not done. Patients are reluc- 
tant to be biopsied a second time; so far I have not asked a patient 
for a third biopsy. The amount of bone needed is still too great and 
the procedure too traumatic to justify such repetitive studies at present. 
HEANEY: You are to be congratulated for attempting this exceedingly 
difficult task; I think it has to be done. Also, I think it is this sort of 
approach that is going to provide us with valuable information, but I am 
convinced from what I have seen so far that much of the discussion of 
the last 2 or 3 minutes is completely irrelevant. We do not know 
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whether the data are themselves dispersed because we have no adequate 
standard of reference. I do not see how we can conclude anything 
except that this is a valuable first step, and we hope we can go on from 
here. 
I think osteoporosis is a diverse disease with many mechmisms, 
many pathogeneses, and many manifestations, but I do not think your 
data show it one way or the other. 
NICHOLS: I agree with you absolutely. We do not have an adequate 
standard of reference yet. Moreover, we do not know enough about 
the details of the cellular mechanisms to begin to interpret what we 
see. 
PRITCHARD: Would you like to know the ratio of osteoblast to osteo- 
clast activity? Suppose you took the ratio of alkaline phosphatase 
to acid phosphatase activity as a measure of the ratio of osteoblasts 
to osteoclasts. Surely, that ought to be a useful index. 
URIST: In the serum or the supernatant? 
PRITCHARD: In the bit of bone. 
NICHOLS: We have made some measurements in other systems, but 
PRITCHARD: You could take the ratio and call it the Pritchard Index. 
TALMAGE: The osteocyte also has these enzymes, so why should you 
be considering only the osteoblasts and osteoclasts? 
PRITCHARD: If the index is a useful guide as to whether the bony 
condition is progressive or not, let us not worry too much about the 
osteocytes. 
FREMONT-SMITH: Have you had any samples of bone from disuse, 
for instance, from polio cases? 
NICHOLS: No; we have not. There is so little paralytic polio now 
that we rarely have such patients, and it is very hard to come by an 
adequate sample. 
So far, we 
can only say that these patients have osteopenia by roentgenographic 
examination. The only thing that tells us that resorption might be 
increased is that one cannot make a case for anything else happening 
on a regular basis. However, now we have a few measurements of 
collagenase activity in human bone and this permits us to categorize 
one small group of osteoporotic individuals more precisely in terms of 
resorptive activity. 
The essence of the technique is similar to that we have described 
for animal bone (ref. ). One takes human bone, grinds cells out 
of it, homogenizes the cells with Triton-X-100, which breaks up the 
lipid membranes, and incubates this mixture with I4C-labeled bone 
collagen for 1 hour. Then the mixture is diluted with ice-cold water 
not in this particular one. 
I would like to turn the discussion now to resorption. 
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and poured into an ultrafilter. The ultrafiltrate from the incubation 
mixture is then dried, taken up in a small volume, and counted. 
It turns out that the counts in the ultrafiltrate are in proline and 
hydroxyproline, when the collagen has been labeled with I4C-proline. 
These counts are present in the same proportions as they are in collagen, 
and their specific activities are similar to what they were in the parent 
molecule, so that it seems likely we are measuring collagenolytic 
activity. The amount of such activity seems to vary directly with the 
DNA content of the homogenate in normals. The mean value ob- 
tained in five such individuals is 8.75 milligrams collagen broken down 
per milligram DNA, with a range off  2 S.D. on each side of the mean 
of 4.4. 
At present we have two measurements in patients with osteoporosis; 
one was 62 years old and the other was 57. The latter is from a lady 
who had been treated with estrogen for some time and had typical 
postmenopausal osteoporosis. The other one is from a man with 
coronary arteriosclerosis and marked osteoporosis -possibly some 
form of osteogenesis imperfecta, because he had a crushed vertebra 
when he was only 33. The point is that these data are just enough to 
suggest that an elevated bone collagenase activity may turn out to be 
still another way of classifying osteoporotic patients. 
TALMAGE: Could I ask one thing concerning your data? Were the 
samples from the osteoporotic individuals taken from the same part 
of the same bone as the samples from the control patients? 
NICHOLS: Yes. 
TALMAGE: All of these were from iliac crests? 
NICHOLS: Almost all. There is one other thing that ought to be 
said; the metabolic activity per wet weight unit, as generally defined, 
varies greatly depending on where one takes the bone sample - head 
of the femur, iliac crest, or rib. However, on the DNA basis the 
metabolic variables do not vary much. 
URIST: DNA is a valid index of cellular activity. 
ARNAUD: You really do not know if some of the results obtained 
might actually be the result of fewer cells doing more work. 
URIST: Whatever the interpretation, Dr. Nichols is quantitating the 
cellular activity in the sample. The method should appeal to Dr. 
Bauer because he has changed the name of the disorder from osteo- 
porosis to osteopenia. 
BAUER: If you have two patients both suffering from osteoporosis 
and one patient is a 36-year-old man and the other a 70-year-old woman, 
you must be very cautious in concluding that these two individuals 
are suffering from one and the same disease. If we define osteoporosis 
as a condition of too little bone and fractures, then many different 
" 
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mechanisms may produce this condition. Etiologically then, the 36- 
year-old man does not suffer from the same condition as the 70-year-old 
woman. 
ARNAUD: I do not think that follows at all. I think they may be the 
same. 
BAUER: Dr. Nichols, 1 am most intrigued by attempts to miniaturize 
your bone-biopsy analyses. 
NICHOLS: I think so. One can just go on making measurements 
because one knows how, but I am not sure this is a terribly valuable 
approach to the problem. This is the reason that I am beginning to 
think that maybe the thing to do is to leave shrinking elderly ladies 
alone until we know a bit more about normal bone-cell processes. 
URIST: Perhaps I can arouse some discussion from Dr. Currey, 
Dr. Sjostrand, Dr. Belanger, and some of the others who do not see 
patients with osteoporosis every day, by showing a few figures to 
illustrate the nature of the problem. 
BUDY: For the record, would someone please define “osteopenia”? 
A working definition would be most useful at this time. 
BAUER: Too little bone. 
FREMONT-SMITH: Good. 
CURREY: The sturgeon has osteopenia. 
HEANEY: As long as someone asked this question, I think when we 
say “too little” we are referring to some frame of reference. Too little 
for what? 
Do you see what I am driving at? 
BAUER: For the normal. 
ROBINSON: The definition ought to be “too little bone tissue for a 
unit volume of whole bone.” 
HEANEY: For what? 
BAUER: I think the simplest is “too little bone, as compared with 
normal.” It does not disturb me too much that this cannot be measured 
very accurately at present. 
HEANEY: It does not disturb me that it cannot be measured out, but 
when we say “too little” it means deficiency somehow, and the very 
word “deficiency” means some frame of reference. Is it too little 
for structural purposes? 
MACDONALD: Yes. 
HEANEY: I quite agree. 
URIST: Besides being too little in amount, the bone in the aged pa- 
tient with typical osteoporosis is defective, degenerate, in part, dead 
tissue. I will substantiate these statements with some figures of pa- 
tients I have seen in the clinic. 
Figure 86 shows a 67-year-old woman with a typical form of severe 
senile osteoporosis in the lateral view (left) and the posterior view 
(right). Note the increase in the length of arms relative to the length 
Is it too little for homeostatic purposes? 
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FIGURE 86. 
osteoporosis. 
Photographs of a 67-year-old woman with a typical form of severe senile 
of the torso. Also, note the deep circumferential skin folds just below 
the costal margins. When the patient was measured with a yardstick 
at monthly intervals, it was clear that her height decreased progres- 
sively, and over a period of 2 years she lost approximately 3 inches in 
the length of the torso. 
In view of the location of the gross changes in the spinal column, 
the best place to do a biopsy on a patient with osteoporosis would be 
on a vertebral body. Unfortunately, this is not readily accessible or 
suitable for obtaining an ample specimen. The next best place is the 
proximal end of the femur on the lateral aspect or the medial aspect 
of the upper tibia. It is customary to assume, but by no means proved, 
that the disease is qualitatively the same in all parts of the skeleton. 
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FIGURE 87. Roentgenographs of osteoporotic spines: (a)  Lumbar spine and (b) dorsal 
spine. 
Figure 87(a) is a roentgenograph of an osteoporotic lumbar spine 
showing ballooned disks, thin anterior cortex, collapse of the third 
lumbar vertebra, and balloon-shaped intervertebral disk spaces. Fig- 
ure 87(b) is a roentgenograph of the dorsal spine of a typical patient 
with senile osteoporosis. Note the collapse of the 6th, 7th, 9th, and 
1 1 th thoracic vertebrae and the upper dorsal kyphosis. 
A reduction in trabecular bone mass, as well as cortical bone, occurs 
and can be determined by measuring the density of the vertebral body 
as an organ (apparent vertebral density). 
The procedure on autopsy specimens, as employed by Dr. Michael 
Gurvey, a postdoctoral fellow in the Bone Research Laboratory at 
UCLA, is as follows: (1) the vertebral bodies are scraped clean of 
ligaments and weighed on an analytic balance, and (2) the volume 
of the vertebral bodies is determined in water, by use of the volume 
of water displaced by the bone, expressed in cubic centimeters. The 
specimens are  then prepared and analyzed for apparent density as 
follows: 
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1. The core of the center of the vertebral body consisting of only 
spongiosa is removed with a 2.6-centimeter hole saw. 
2. The core of spongiosa is washed under a stream of cold water to 
remove all soft tissue elements (bone marrow, vessels, blood, and so 
forth); it is then cut into disks of 1 to 2 centimeteis in thickness with 
a band saw. 
3. The disks of spongiosa are agitated for 24 hours in cold tap water 
on a shaking machine to remove soft tissue cells. When the process 
is complete, the color changes from yellow to white. 
4. The disks of washed bone are defatted in a Soxhlet apparatus by 
refluxing for 24 hours in a 2-to-I solution of chloroform and methanol; 
then they are dried in an oven at approximately 80" C for at least 
72 hours or until they reach a constant weight. 
5. After weighing on an analytic balance, the volume of each disk 
is determined by measuring the dimensions with a sliding caliper and 
using the formula, r2 times height; the volume is expressed in cubic 
centimeters. 
6. Apparent density of the spongiosa disks is then calculated from 
the weight per unit volume and in grams per cubic centimeters. 
Five gradations from five different subjects are shown in figure 88. 
Only the subjects with bone density of 0.128 and 0.107 had spontaneous 
fractures, or pathologic osteoporosis. These patients had approxi- 
mately 40 percent of the bone mass, or apparent density, of the average 
nonosteoporotic young individual at age 30. 
Using the method described in the preceding paragraphs, the ver- 
tebrae were used to construct a spondylometer for use in patients with 
osteoporosis. A spondylometer is defined as a scale for comparing 
normal and abnormal radiopacity with the aid of the naked eye; it 
reveals the distribution, quality or structure, and quantity of bone 
tissue. Figure 89(a) is a roentgenograph showing the spondylometer 
and the lumbar spine of a 50-year-old nonosteoporotic woman. The 
radiopacity of the second lumbar vertebra corresponds approximately 
to the bottom vertebra, or to the most dense on the column of the 
spondylometer. The vertebra in the top of the spondylometer is from 
an osteoporotic patient and shows deformity from an old fracture. 
Figure 89(b) is a roentgenograph of the spondylometer and the lumbar 
spine of a 70-year-old woman with severe osteoporosis. The radio- 
pacity of the first and second lumbar vertebrae correspond to the 
radiopacity of the top two segments of the spondylometer that were 
removed from autopsy subject with severe osteoporosis. The first 
lumbar vertebra has collapsed, while the second is biconcave. 
We have also performed biopsy studies on patients with severe 
osteoporosis before treatment to exclude other disorders, such as osteo- 
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FIGURE 88. Photographs (top row) and roentgenographs (center and bottom rows) 
of specimens of bone from osteoporotic subjects taken from center of vertebral bodies 
with apparent densities (left to right) of 0.256, 0.243, 0.157, 0.128, and 0.107. Note 
that the trabeculae are not simply reduced in number. The vertical trabeculae increase 
in thickness as the horizontal trabeculae are resorbed. These changes in the structure 
of the spongiosa occur while the cortical bone decreases progressively in thickness. 
malacia, osteitis fibrosa, multiple myeloma, and so forth (ref. 105). 
FREMONT-SMITH: What bone did you biopsy? 
URIST: The lateral aspect of the upper end of the femur; also the 
medial cortex of the proximal end of the tibia in patients with severe 
osteoporosis of the spinal column. Unfortunately, the spinal column 
is inaccessible for biopsy on aged individuals. We made cell counts, 
which are summarized in table XIX and observed an overall difference 
of 6 percent more dead bone in the tibia and femur of the osteoporotic 
than the nonosteoporotic. The difference may be greater in the 
vertebral bodies of the two groups, but we do not have data to prove this. 
NICHOLS: This is dead bone as judged by empty lacunae or calcified 
cells? 
URIST: Yes. 
HEANEY: Dr. Nichols, why are you reluctant to call that dead bone? 
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FIGURE 89. 
nonosteoporotic woman and ( b )  a 70-year-old woman with severe osteoporosis. 
Roentgenographs of the spondylometer and lumbar spine of (a) 50-year-old 
NICHOLS: Because I think that just because a particular individual 
cell or set of cells is dead, it does not mean that the bone is necessarily 
dead any more than that it is necessarily alive when it has an intact cell 
in it. This is important because what we are talking about right now 
is a cell type that has a job to do which it is or is not doing. Cells on 
the surfaces may be performing quite normally while some in the depths 
may not, and vice versa. Really, all bone can be called “dead” because 
most of it is nothing but a collection of extracellular collagen which is 
calcified. 
CURREY: Oh, no, no. 
FREMONT-SMITH: The keywords were “nothing but.” If you had 
left out the “nothing but,” everybody would agree. 
CURREY: By what criterion do you say there is no difference between 
a bone that is chock-full of healthy osteocytes and bone that is chock- 
full of mineralized osteocytes? Are these the same as regards life 
and death? 
I say 
calling a bit of bone alive or dead so far as the calcified matrix is con- 
cerned is an improper use of the term. 
CURREY: But you are only talking about 99 percent of bone when 
you are talking about calcified matrix, and the other percent is very 
important. 
NICHOLS: Clearly, not so far as the osteocyte is concerned. 
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NICHOLS: Agreed. What I am saying is that we should refer to an 
osteocyte as dead, rather than saying the bone is dead. Do you agree 
with this thought? 
B~LANGER: Oh, of course, very much so, because this sort of thing 
can be followed by a lot of activity at the surface, either bone growth 
or osteoclasia, and these two types of cells in the bone are not dead at 
all. The osteocytes are dead inside. 
NICHOLS: I think this has great implications in how tissue behaves. 
HEANEY: But that microscopic volume is certainly dead. One does 
not say the whole femur is dead because it has a few microscopic areas 
of empty lacunae. 
HOWELL: Is the method of fixation and embedding such that you are 
not knocking a soft little particle out of a solid sheet of bone? There 
could be some difference in ease of removal of the soft part rather than 
actually not being there in the first place. 
URIST: Fixation and artifacts are certainly a cause for concern. 
However, the empty lacunae in an osteoporotic individual are also 
actually enlarged. This is described in the old literature in various 
bone diseases as slow necrosis, oncosis, cell necrobiosis, or osteo- 
necrobiosis. There are all gradations of oncosis. It occurs in normal 
aging of bone and accounts for a steady increase in the amount of dead 
bone in the skeleton with time. The question is whether the process 
is accelerated, accentuated, or exacerbated in osteoporotic compared 
with nonosteoporotic persons. 
HOWELL: If your thesis is correct, that the axial skeleton lumbar 
spine is the seat of the worst disease, autopsy changes should not alter 
this hard-tissue phenomenon you describe, and therefore you ought 
to be able to document how consistent or how prevalent these changes 
are in the axial skeleton. 
CURREY: There were two figures you mentioned, of 28 and 22 per- 
cent dead cells, which you said was not a great difference, but the two 
types were very consistent. This surprises me. I do not know what 
your standard deviations were, but for the counts that I did on healthy 
nonosteoporotic people, 1 would certainly never have been able to 
distinguish between 28 and 22 percent, except perhaps on an enormous 
series; however, you are quite happy that the variance was sufficiently 
small for you to distinguish between them. 
URIST: The 6-percent difference is based on a sample of 10 000 cells 
counted by three people working independently. 
CURREY: This is just in two different people? 
URIST: We have biopsies on 24 cases of severe osteoporosis and on 
10% cases of nonosteoporotic persons of comparable age with osteo- 
arthritis in various joints. 
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PRITCHARD: This material is very difficult to fix adequately; I th 
that some of the spaces you said were empty had cells in them, but 
there seemed to be some that showed fixation artifacts. 
URIST: You are quite right; but to deal with this possibility the re- 
tracting osteocytes were counted separately, as shown in tak’le XIX. 
PRITCHARD: Were they reactive? There is the possibility of error 
here. 
URIST: Let us go on and see more material from autopsy subjects. 
BELANCER: May I say something on this topic of empty lacunae and 
dead osteocytes? This is a phenomenon which one can obtain pro- 
gressively with hyperparathyroidism in animals, such as we have done 
with Dr. Krook at Cornell on horses. As the disease or syndrome 
progresses, the number of these things increases, and one can follow 
also the death throes, if I may say so, of the osteocytes in this type of 
material, so it is certainly no artifact. 
URIST: McLean and Bloom (ref. 140) described osteonecrobiosis 
in experimental hyperparathyrodism in rats. 
A good survey of pathologic osteoporosis on autopsy subjects is 
difficult to complete. The reason is that patients with severe patho- 
logic osteoporosis are long-lived and healthy; therefore, they appear 
relatively infrequently in university teaching hospitals for autopsy. 
We would like to obtain data like that shown in figure 90 from 50 pa- 
tients with severe osteoporosis, but we find that less than l percent 
of autopsy subjects have severe osteoporosis comparable with that 
found in 85-year-old white healthy females. 
NICHOLS: How did you get the marrow out? Are the specimens 
dried first? 
URIST: The marrow was removed by cold-tap-water agitation on a 
shaking machine, and then refluxed for 24 hours in chloroform and 
methanol in a Soxhlet apparatus. 
PECK: Do you have any technique for measuring the interstitial 
volume? I should not have said “interstitial volume,” I should- 
URIST: We have not measured the intertrabecular interstitial volume, 
but that could be done. 
NICHOLS: Your point is important because in our data we cannot 
find any difference in metabolic activity on a DNA basis between the 
ages of 40 and 80. If anything, the cells are a little more active in 
older people. 
URIST: The cells may be more reactive, but in terms of the net change, 
bone mass diminishes with age. Reduction of bone mass with age has 
been measured by Trotter el al. (ref. 159) on whole bones, Arnold 
(ref. 160) on blocks of bone, and Jowsey (ref. 16 1) on microradiographs. 
I think there is some-but not much-stable information in this 
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FIGURE 90. Radiographs showing a four-organ preparation from a 
nonosteoporotic autopsy subject, male, age 67. The tissue in the 
upper left is skin; lower left, fascia; upper right, first and second 
lumbar vertebrae; lower right, aorta. Samples of tissue from the four 
organs were analyzed for total calcium, total phosphorus, hexosamine, 
and collagen in an effort to determine whether mineral was trans- 
ferred from bone to soft tissue in patients with osteoporosis. The 
results on approximately 39 consecutive autopsy subjects were 
equivocai. 
field that is valuable and that we can respect. I do not think every- 
thing is chaos. 
Tables XX and XXI demonstrate that approximately one of every 
four white healthy females, average age 85, in the United States, has 
severe osteoporosis; one of every seven debilitated, inactive, chron- 
ically ill white male, average age 66, has a moderate degree of osteo- 
porosis. Statistics for healthy men in the seventh decade are not 
available. The period of life expectancy of the average male is less 
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TABLE XX 
CONDITION OF THE SPINE IN 100 CONSECUTlVE WOMEN (AVERAGE AGE 85) 
Percent 
I 
Generally negative, good bone density.. .................................................... 
Spondylosis, good or increased bone density. ............................................ 
Osteoporosis (diagnosis based upon collapsed vertebra). ........ 
Compression fractures of the dorsal spine ................................................ 
..... 
Biconcave lumbar vertebra .................................................................... 
Generally negative, good bone density .................................................... 
Spondylosis, good or increased bone density. .......................................... 
Osteoporosis (diagnosis based upon collapsed vertebra). ............................ 
Compression fractures of dorsal spine .................................................... 
Biconcave lumbar vertebra .................................................................. 
Compression fractures of lumbar vertebra. 
Compression fractures in both dorsal and 1 
Fractures of the hip ............................................................................ 
Spondylosis and osteoporosis.. ...... 
Severe kyphosis with spondylosis. .. 
Severe kyphosis, osteoporotic (from 
Severe kyphosis, Scheuermann’s ty 
9 
70 
18 
27 
14 
15 
9 
10 
J 
11 
0 
I 
than that of the average female. The human female is one of the longest 
lived of all mammals. 
FREMONT-SMITH: The men were much younger, were they not? 
URIST: The average age was 66 years; the average for the women was 
NICHOLS: I think your group of males was unusually short-lived. 
URIST: The question that arises now is whether physiologic reduction 
of bone density with aging or inactivity (without collapsed vertebrae), 
pathologic ‘osteoporosis, and multiple spontaneous fractures are dif- 
ferent degrees of one and the same process. Our working hypothesis 
85 years. 
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is that excessive or  extensive osteonecrosis of the cortical bone of the 
vertebral bodies is a characteristic of pathologic osteoporosis, but we 
do not have sufficient data to prove it; also, we have no idea of the 
cause of the necrosis. Don Fareed, a medical student research fellow, 
is making cell counts on cortical bone and perfusing the blood vessels 
of autopsy specimens. 
NICHOLS: Dr. Bauer has a few figures to show which complement 
what Dr. Urist has been talking about. Because it is clear that we do 
not know much about changes in biosynthesis in the etiology of this 
disease, we ought to take a look at our knowledge of resorption and its 
disturbances to see if we can learn something from the animal models 
now available. 
BAUER: I would like to present some data on the incidence of frac- 
tures in the population of Malmo, Sweden. Figure 91 (ref. 162) shows 
the annual incidence per 10000 inhabitants for fracture of the distal 
end of the radius in males and in females. At about age 40 there occurs 
a sudden dramatic rise in the incidence of this fracture in females. 
Figure 92 shows that there is a distinct difference between the two 
sexes also as to what has caused the fracture. The figure shows the 
ratio of slight over severe trauma, slight trauma being defined as a 
fracture occurring from a fall on the floor or something similar; if more 
trauma was involved, then it was registered as severe. We see again 
a very distinct difference between the two sexes. 
In figure 93 we see, in the same population, the change with age in 
location of fracture of the radius. With increasing age the incidence 
of distal fractures rose in relation to shaft fractures, and dramatically 
more so in females as compared with males. This again suggests that 
something is happening in the skeleton with age, and more so in females 
than in males. 
Figure 94 (ref. 163) shows the incidence, in the same population, of 
fracture of the distal end of the radius and of the neck of the femur. 
There is a parallel rise in the incidence of these two types of fractures 
with a lag period of some 16 years. 
I show the diagram (fig. 95, ref. 164) to illustrate that one cannot 
relate fracture immediately to fragility of bone, Fracture in general 
can be caused by external violence or by disease; cancer metastasis 
or radiation injury, for example, tend to make the neck of the femur 
weaker than normal. But when one is looking at data of this type, one 
cannot escape the conclusion that in addition to external violence and 
such diseases, which we can define at the present time, something is 
happening in the skeleton that is closely related to age, and also that 
this progressive age factor, fragility, is an important factor in causing 
certain fractures in the aged. 
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If we are interested in trying to understand this age-linked fragility 
of the skeleton, we have to make a distinction between two mechanisms 
for making the skeleton fragile. One is too little bone, and the other 
may be, and this is relatively hypothetical, a change in the quality of 
the bone tissue. Unless we try to make this distinction, we will tend 
to overlook the possibility that fracture may occur because the skeleton 
is weaker than normal without there necessarily being any less bone 
than normal. 
I submit that the epidemiologic data on fractures of the distal end of 
the radius in females are especially difficult to interpret solely in terms 
of too little bone. It is quite clear that the skeleton loses bone with 
age, but nobody has shown that the female at age 40 or 45 has lost 
enough bone to cause this rise in fracture incidence. 
Therefore, I believe it is important to measure the strength of bone 
independent of how much bone there is. 
One could then say that osteoporosis may be defined as a disease 
in which there is fracture from inadequate violence; one etiologic factor 
may be “osteopenia,” meaning too little bone, and another “fragility,” 
meaning a condition where the quality of the bone tissue has deterio- 
rated. The question was raised: “Too little as compared with what?” 
Naturally, too little as compared with normal. 1 do not think one must 
show that it is bad to have too little bone compared with normal any 
more than one must show that it is bad to be underweight or overweight. 
It is true that because we can link sideropenia to definite symptoms of 
disease, it is beyond doubt a distinct disadvantage to have too little 
iron; and it is very definitely bad to have too little money, even though 
what is normal is hard to define. Even though “underweight” is not 
defined in terms of one weighing so little as to be blown into the ocean 
by a gale of, say, 20 miles per hour, it is possible to say that outside 
of two sigmas of normal, one is underweight; then one is able to deter- 
mine if it is bad to be underweight. In the same way, I think one can 
very well talk about a condition of too little bone, even though perhaps 
it is difficult to measure, and even though one does not know whether it 
is bad to have it. 
NICHOLS: Then you would put osteoporosis into my category of 
disturbance of cell machinery; the difference being that you believe it 
is an acquired, rather than a congenital, disturbance; is that correct? 
In other words, do you think something goes wrong with the machinery 
so that the way in which the bone is made is wrong? 
I think it probably is. 
BAUER: I do not have any ideas about the etiology here. 
NICHOLS: I am serious. This is a possibility. 
.BAUER: That is why I am so serious. I have not talked about the 
etiology. To give an example of what I am talking about, one could 
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say that perhaps the quality change comes about because of’ a change 
in polymerization or crosslinking; perhaps the collagen fibrils suddenly 
become tired and do not bite each others’ tails as well as they should. 
But it is a very interesting fact that this possibility has not been dis- 
cussed and even less studied. 
MCLEAN: I think it should be pointed out that there is not too little 
bone for the metabolic functions of the skeleton, which hold up very 
well. 
BAUER: Oh, yes. 
MCLEAN: It is too little bone for the structural functions of the 
skeleton. 
BAUER: I am trying to say that I do not know whether it is too little 
for metabolic function or too little for a structural function. I define 
“too little bone” as being less bone than normal in the skeleton, and 
I would like to know what structural importance this has. I am betting 
on the possibility that if I have less bone than normal, my skeleton 
becomes somewhat less strong than normal; but 1 keep in the back of 
my mind the possibility that without a quantitative change in my skele- 
ton, qualitatively perhaps something happens which makes it more 
brittle. 
MCLEAN: But you do agree that in osteoporosis the skeleton main- 
tains its metabolic activity at approximately its normal level. 
BAUER: Yes. 
MCLEAN: I t  seems to me that it is important to differentiate between 
the inability of the skeleton to withstand strain and its ability simul- 
taneously to keep up metabolic activity. 
NICHOLS: What you are saying is that while one end of its function 
is OK, the other end may be in trouble. 
HEANEY: But that is an assumption, and this is what I think Dr. 
Bauer is trying to say and has been trying to say for many years. J 
recall puzzling over this at prior conferences. There is too little bone 
in comparison with normal reference standards, and there is, associated 
with this, an increased liability to fracture. But it is another thing 
entirely to say that the too little bone causes the fracture. 
If you 
take, say, Dr. Urist’s elderly ladies and you find that they have too little 
bone and they have fractures, or 26 percent of them have fractures of 
the spine, one should not jump to the conclusion that the reason they 
have fractures is that they have too little bone. I t  may be that there 
is a poor quality of bone, also. 
MACDONALD: Is this not easily demonstrable by tensile-strength 
measurements? 
CURREY: Well, there are practical difficulties. I think one could 
BAUER: No, no. The thing is that you have too little bone. 
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calculate, quite reasonably, simply the reduction in the strength that 
you would expect from loss of bony material. I think there is no doubt 
that, in fact, there is also a change in the quality of the bone. The 
highly calcified regions are certainly centers which will shatter under 
impact in a way that ordinary bone would not. ’To separate the two, 
the change in the quality of the bone and the change in the amount of 
bone, and to separate their effects on fracturability of the whole bone 
is feasible, but technically very difficult. Certainly, it would be a very 
good thing if someone could get down to it. 
BAUER: There is definite lack of correlation between attempts to 
test bone strength in vitro and the clinical evidence of bone fragility 
deduced from epidemiologic data. This is most embarrassing when we 
realize that we are talking of, by far, the most important metabolic 
bone disease we have. Twenty-five percent of Dr. Urist’s elderly 
ladies have fracture of the vertebrae, and it has been shown in other 
series; in Denmark, for instance, about 25 percent of all inmates of 
homes for the aged have fractured vertebrae without knowing that they 
have it and without knowing that they have ever had any trauma. 
Fractured vertebrae is thus usually a very mild disease. But this is 
not so in fracture of the neck of the femur, which occurs in 20 percent 
of all women who reach 80. Fracture of the neck of the femur is not a 
catastrophe to those who have it; but it is catastrophic to society, not 
because these females would work very hard if they did not have frac- 
tures but because young people have to take care of them. 
I submit that this is, in a way, what we are all studying; prevention 
of fracture in the aged is the man-on-the-moon project of bone 
metabolism. 
NICHOLS: I agree with you, Dr. Bauer. There are some other ways 
of studying this problem that we ought to cover in this session. 
NICHOLS: I presented the data that I did earlier because I wanted to 
indicate that one really cannot, from available metabolic data, make 
any sense out of the problem at all. I am not sure that one can do much 
better studying resorptive activity either. The fact is that we need 
some animal models, of which there are now a few. Whether these are 
models of osteoporosis is a matter which we might debate. 
Dr. Raisz has been looking into Jenifer Jowsey’s “osteoporotic” 
cats, and I hope he will tell us about them. 
RAISZ: I would like to comment on the point about the difference 
between the supportive and the homeostatic functions of the skeleton. 
As Dr. McLean pointed out, the homeostatic function may be primary 
so that metabolic activity is maintained at the expense of support in 
some situations. I believe that the osteoporotic cat which Dr. Jowsey 
has been studying is an animal model for this, although I must admit 
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that at first I was reluctant to accept this model. While we agree that 
human osteoporosis may have many etiologies, I do not think we need 
to throw out the possibility of a common denominator. We do have an 
animal model, observed in many different species, for the effects of 
calcium deficiency. Calcium deficiency in different animals and in 
different growth states can produce typical secondary hyperparathy- 
roidism or it can produce a state which is histologically typical of 
osteoporosis. Dr. Jowsey has been producing osteopenia in the adult 
cat by giving a high-phosphate, low-calcium diet; we have wondered 
whether this model might teach us anything about osteoporosis in man. 
There are two aspects of these animals which obviously require study. 
One is their parathyroid activity. We have been studying this activity 
in a number of such animals by measuring their parathyroid size and 
parathyroid amino acid uptake after long periods of calcium deficiency. 
These animals had normal fasting serum calcium concentrations. 
Homeostasis appeared to be preserved, while parathyroid activity 
was increased twofold to threefold as measured by the parathyroid 
activity index to which we referred earlier. This is far from the ideal 
measurement, and these questions will be clarified when good blood bio- 
assays for parathyroid and other calcium-regulating hormones are 
readily available. Nevertheless, we wondered why parathyroid ac- 
tivity was increased with no change in fasting serum calcium. (We had 
seen small changes in fasting serum calcium concentration with diet in 
the rat.) This appeared to be a deranged feedback; however, Dr. 
Jowsey has found that these animals do have a period of hypocalcemia 
during the absorption of their diet. The animals are maintained fairly 
hungry and fed a restricted diet of meat all at one time. With this diet 
they get a large phosphate load and their serum calcium concentration 
actually falls postprandially. 1 have not seen any data to determine 
whether individuals with osteoporosis or other serious bone disease 
have any derangement in the stability of their serum calcium concen- 
tration; possibly Dr. Copp can explain this. Do some patients with 
osteoporosis or other chronic bone disease have instability of the 
serum calcium concentration, even though a normal homeostasis is 
maintained most of the time? 
COPP: We found the diurnal fluctuations in plasma calcium concen- 
tration in osteoporotic individuals to be small and within normal limits. 
NICHOLS: We too have done some calcium and EDTA i n h i o n  tests 
on osteoporotic patients and can find no differences from normal. 
RAISZ: Another thing which Dr. Belanger will comment on, is the 
dead-cell problem. Apparently the dead-cell incidence is high in 
osteoporosis and high in the various forms of that thing which ranges 
between nutritional secondary hyperparathyroidism, which is what Dr. 
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Belanger was studying, and that thing which Dr. Jowsey calls calcium 
deficiency osteoporosis. I think we ought to look at these parameters 
more in these animals and in man. 
COPP: I would like to make a comment here, because in young 
phosphate-deficient rats you get the same picture (ref. 165). Mineral 
is lost rapidly from the skeleton to provide phosphate essential for the 
soft tissues. They have very severe osteopenia and die because of 
collapse of the demineralized rib cage. 
NICHOLS: There is another animal model- heparin osteoporosis - 
which is useful because it avoids the whole issue of hyperparathy- 
roidism, which is a special disease but may well be the cause of the 
osteoporosis in the models cited so far. 
BAUER: I can add that if you feed tigers on tiger hearts, they will 
develop severe osteopenia; or cats on beef hearts, which is a more 
common type of experiment. 
NICHOLS: Some time ago a man was referred to us because the 
severity of his osteoporosis prevented his working; this man also had 
a coronary artery disease for which he had been receiving large doses 
of heparin for a long time, and it was quite well controlled. A vari- 
ety of things suggested that his osteoporosis and his heparin therapy 
might be related (ref. 166), and this suggestion led to the animal model 
I would like to talk about. Figure 96 is a roentgenograph of the spines 
of two rats, one of which was kept anticoagulated with heparin around 
the clock for a month by John Asher in my laboratory. If you stretch 
your imagination, the one on the right looks a little less dense. As 
some of you know, Tourtellotte in Philadelphia, using sulfated low- 
molecular-weight dextran, produced more striking changes. I think 
his drug is probably a better agent than heparin because it induces less 
bleeding, but this is a peripheral problem. The point of importance 
is that the probable mechanism involved in the heparin-induced effect 
has now been worked out (ref. 167). 
If you remember my diagram outlining the biochemistry of the bone 
cell, lysosomes containing collagenase were mentioned. These, it turns 
out, are lysed by heparin in vitro as is shown in figure 97. Heparin at 
50 pg/mg has little effect, but at 2500 there is clearly release of col- 
lagenase from the large-granule fraction of bone-cell homogenates 
which contain these lysosomes. Whether there is truly an inhibition 
at 10 000 pg/ml, I am not sure. 
Since, from these observations, it appeared that heparin releases the 
latent collagenase in bone-cell lysosomes in vitro. we wondered whether 
the changes in bone density in chronically heparinized patients or ani- 
mals might be related to some effect of the heparin on the stability of 
lysosomes in their normal location in cells in vivo. 
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FIGURE 95. Diagrammatic representation of etiologic factors in fractures 
of the proximal end of the femur. [Adapted from ref. 164; reprinted by per- 
mission of the publisher.] 
The results of our investigation of this possibility are illustrated in 
figure 98. Two sets of data are shown for lysosomes derived from 
bone of normal and heparinized animals. Saponin-induced activity 
is equivalent to the total activity present in the fraction, while “spon- 
taneous’¶ activity is that released spontaneously during incubation, 
presumably because of lysosome leakage or rupture. The ratio be- 
tween the two can be considered an index of the relative resistance of 
the lysosomes to mechanical trauma. Simple inspection shows that 
heparin treatment increases total collagenase activity and the relative 
as well as the total amount released spontaneously. In other words, 
the bone-cell lysosomes in heparin treatment are more easily lysed 
(ref. 168). Since increased collagenase goes with increased resorption 
(ref. 169), these data give us an explanation for this type of osteoporosis 
in which no change in biosynthetic rate occurs. In contrast, one can- 
not demonstrate a change in the stability of the lysosome at all in para- 
thyroid-treated animals, although one can demonstrate more total 
collagenase activity in the lysosome fraction. 
So this is another animal model which is now available for study. 
This brings us to considering how bone is resorbed. Dr. Belanger 
has some figures of what happens in osteolysis, a phenomenon which 
may hold some keys to understanding osteoporosis. 
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BELANCER: I wonder if you would like to see some figures which 
demonstrate the phenomenon that I mentioned a moment ago and how 
this fits into the animal model. 
FREMONT-SMITH: Yes, by all means. 
BELANGER: “Osteolysis,” an old word which we find in dictionaries, 
but with various definitions, we would now like to reserve for an activity 
which takes place in the depth of the bone and an activity which is, 
it appears, related to the osteocyte at the time when this osteocyte 
acquires its maturity. 
This sort of activity can be seen in trabecular bone as related to the 
center of the trabecula, and it is manifested by an enlargement of the 
lacuna. 
When we do autoradiographs of thymidine-labeled bone we know that 
the thymidine appears first in the precursor cells which are outside the 
bone trabeculae. Then it passes out into the osteoblasts, then to the 
osteocytes of small size which are near the surface, then into the large 
osteocytes which are in the center of the trabecula, and finally this 
radioactive label of DNA disappears completely. 
The time required for these labeled cells to go from the osteoblast 
stage to the last stage of matvre osteocytes, of course, varies from one 
area to another of the body and varies with the age of the animal. The 
younger the animal, the faster this takes place. In the vertebrae of a 
rat, this lifespan of a bone cell is approximately 4 days. 
YOUNG: How do they move through bone in 4 days? 
B~LANGER:  Figure 99(a) is what we call an alpharadiograph of soft 
tissue. In  this case, we have removed the mineral and have obtained, 
through bombardment with alpha particles, a density image of the tissue. 
The periosteum and the bone trabeculae are shown, and we can see 
now that the density of the organic matrix is far greater at the periphery 
than at the center of the trabecula, which is contrary to the degree of 
mineralization. We recognize this large lacuna in the center of the 
trabecula. 
Now, as Dr. Young asks, “How do things ‘move’?” We think that 
they move because large osteocytes, before they die, are actually 
perfectly capable of producing proteolytic enzymes which destroy the 
matrix around them and release the mineral, so that there is a con- 
tinuous new stream of bone material from the surface to the center of 
the trabeculae as these cells die out, as the matrix is broken down and 
as the mineral is released. And so the bone which is here at any one 
time is not the bone which was there half an hour earlier. 
Just to show the affinity of these effects, here is some material that 
I have obtained from Dr. Copp. Figure 99(b) represents a parietal 
bone of a sheep in which we can see these spaces, and then lacunae 
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FIGURE 96. Roentgenograph of spines from two rats: Control (left) 
and anticoagulated with heparin (right). 
with osteocytes which are either small or large in a normal sheep. 
Figure 99(c) shows Gone from a sheep that had been infused with 
EDTA intravenously for a period of 4 hours. We see again a very 
large number of large lacunae. 
In figure 100, corresponding to the presence of these large lacunae, 
we also can see, after toluidine blue staining, that there is an increased 
amount of metachromatic material, both inside the lacunae and outside 
in the matrix which surrounds these cells. This was the first phenom- 
enon which we observed, and we attached considerable importance to 
the presence of these acid mucopolysaccharides, thinking that they had 
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FIGURE 97. In vitro effect of heparin on large-granule collagenolytic activity. 
a great deal to do with changing the pH level and releasing the mineral. 
CURREY: Have you got a control picture to that one? 
BELANGER: No; I do not have. 
CURREY: This is rather the same point Dr. Pritchard brought up. 
BELANGER: This has been in the literature so long I did not think 
anybody would be interested; this has been in the literature for many 
years. 
BAUER: It still may be true, though. 
BELANGER: Oh, yes; right. 
PRITCHARD: Dr. Belanger, there is another possible explanation. 
The first bone laid down under the periosteum, or the first bone laid 
down in the metaphysis, is of different character and quality from the 
bone laid down a few days later. The first bone laid down has irreg- 
ular, coarse fibers and big cells. The later bone that buries the first, 
bone has finer, more regular fibers and small cells. Now, how can 
one be sure that this is a dynamic process and not just two kinds of 
osteocytes? 
BELANGER: This is an adult animal, and in the work which we did 
with labeled cells we know that this bone has been totally replaced in 
3 or 4 days. 
YOUNG: Figure 101 shows a region of woven bone and a portion 
of-lamellar bone. The question that some of us raise is whether those 
cells in the center of the trabeculae you showed, those cells that have 
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FIGURE 98. Large-granule collagenolytic activity, 
enlarged lacunae and are stained differently, simply may not represent 
the larger osteocytes characteristic of woven bone, rather than 
osteolysis. 
BELANGER: I do not worry too much about that particular point, 
because we later came up with a more important observation. This 
factor may be more significant because it may contribute to the destruc- 
tion of the organic part of the matrix. We took photographic plates 
that have been blackened inside and processed. Over these we put 
a drop of trypsin and placed pieces of different types of tissue in a 
buffer of pH 7 on the film. We put a piece of pancreas, sections of 
fresh bone, and a section of bone that had been fixed in formalin for 
5 minutes on the film. The pancreatic tissue made a hole in the film. 
The formalin-fixed bone did nothing. The fresh-bone sections made 
a considerable hole in the gelatin, tending to show, I believe, that this 
little piece-of bone actually contains an enzyme capable of doing the 
same thing as the pancreatic tissue or trypsin. 
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FIGURE 99. Alpharadiographs of demineralized bone sections. (a) Dog vertebra: 
Note the dense matrix of trabeculae as compared with periosteum (bottom); note also 
the enlarged lacunae and osteolysis in the trabecula (center). 114X. (6)  Parietal bone 
of a normal sheep: Areas of low density in the matrix are seen in the vicinity of the 
larger lacunae. 182 X. (c) Parietal bone of a sheep infused with EDTA for 4 hours: 
The large lacunae are more numerous and confluent in some areas. 182 X. 
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FIGURE 100. A portion of the tibial diaphysis of a 
horse on a high-phosphate diet for 7 weeks. Note the 
large osteocytes surrounded by metachromatic matrix. 
136X. 
When we do this sort of thing on actual section it is possible to pin. 
point the site in the bone where this proteolytic enzyme, or enzymes, 
come from. 
URIST: Is this a histochemical preparation that is analogous to what 
Jerome Gross and George Nichols observed with quantitative methods 
on tissue cultures and explants? 
BELANGER: Yes; that is correct. This is the so-called reaction of 
Adams and Tuqan (ref. 170), which was devised in England and makes 
use of the same principle of breaking down gelatin. 
PECK: The ability to break down gelatin is the property of many, 
many enzymes. The abiljty to break down native collagen is a prop- 
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FIGURE 101. Region of parietal bone from a 26-day-old rat. Note 
that in the woven bone (top) the osteocyte lacunae are large and closely 
spaced, and the intervening collagen bundles are irregularly arranged. 
In  the lamellar bone (bottom). the lacunae are smaller and farther apart, 
and the collagen bundles are more densely packed in regular array. 
Gomori silver stain. 1250X. 
erty of collagenase; this is what Dr. Gross and Dr. Nichols have 
demonstrated. 
BELANGER: Of course. 
URIST: I understand that this is not collagenolysis, which is some- 
thing else. I also understand that when you use the term “collagenase” 
you are talking of an enzyme that breaks protein down to amino acids, 
but when you are talking about collagenolytic enzymes it is not neces- 
NICHOLS: When you talk of collagenase at present, you are talking 
about an enzyme which works to break down a native collagen mole- 
cule (the “nativeness” of the collagen molecule needs definition in its 
own right) into reasonably large peptides. The further degradation 
of those peptides probably depends, as far as we understand the process 
at the moment, on a peptidase; but the question of whether this is the 
same enzyme as these more nonspecific proteases, which are clearly 
present in the cell and are active both at neutral pH (ref. 169), remains 
unanswered. 
BELANGER: When you do this sort of thing on the bone section, this 
is actually a unicellular response which we get in the center of trabecu- 
lae where each of these large osteocytes is located (fig. 102). There 
is- a ring of tissue destruction immediately surrounding the lacunae 
there. 
sarily so. 
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FIGURE 102. Microradiograph of an undemineralized section 
of the femur of a frog. Note the low density of perilacunar bone. 
520X. 
Figure 103 is a gross type of operation that we made last summer, 
using frog bones. These are femurs and humeri from two tadpoles 
that had been injected with a single dose of 5 units of PTE. You can 
see by the size of the reaction which we have recorded on the film 
that, indeed, PTE has increased considerably, on the average, the pro- 
duction of protease by these pieces of bone. If we drew these out, 
cut the drawings and weighed them, the proportional increase could be 
obtained; this has been found to be sixfold. 
That this might also be related to the production of collagenase- 
and this is where we join our friends Gross and Lapiere in Boston-is 
suggested by the fact that these tadpoles have been injected with para- 
thyroid hormone. We have measured the total length of the animal 
after 1 day .of parathyroid-hormone treatment and compared it with 
controls. Starting with a length of 12 centimeters for the total tad- 
3 1 1-496 0-68- 1 7 
248 Biology of Hard Tissue 
FIGURE 103. Protease reactions from bisected femurs (top) and humeri (bottom) of 
normal tadpoles (two on the left) and tadpoles treated with PTE (two on the right). 
pole - and this is at the time when the tail is resorbing very rapidly- 
after 1 day the controls were 11 centimeters long and the parathyroid- 
hormone-treated animals were 9 centimeters long. So it is from the 
tails of these tadpoles, I believe, that Gross and Lapiere (ref. 171) 
isolated collagenase. I think that the collagenase is affected by the 
system, as well as the protease, which we have demonstrated in the 
bone cells. 
If you would be interested to see the cells that produce this enzyme, 
we have some electron micrographs. 
NICHOLS: I think it should be pointed out in confirmation of Dr. 
Belanger’s ideas that Gilbert Vaes, working in Gaillard’s laboratory, 
has measured the release of various bone lysosomal enzymes in tissue 
culture and found 8 to 10 times more enzyme when parathyroid hor- 
mone was added to the culture medium. Moreover, the total enzyme 
content of the culture medium after incubation was far beyond the 
enzyme content of the tissue originally transplanted, so that this phe- 
nomenon is clearly representing a stimulus of biosynthesis and not 
just increased release of preformed material (ref. 172). 
BELANCER: These are micrographs from 2-day chick embryonic 
tibias, a system which actually replaces itself very rapidly. First I 
will show some figures belonging to Professor Baud (ref. 173) from 
Geneva and published in 1962, where he showed that in bone he could 
see osteocytes in what he called smooth lacunae, and these were at the 
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FIGURE 104. 
cell is closely encased by the matrix. 
chondria are prominent features. 
Peripheral osteocyte from the tibia of a 2-day-old chick embryo. The 
Endoplasmic reticulum, ribosomes, and mito- 
surface of the bone. They were osteocytes that were embedded in 
much larger lacunae in which the wall appeared to be rough. 
In our own chick material (fig. 104) a young osteocyte is located near 
the surface. Actually, we can see that it fits quite neatly inside its 
lacuna and that it has most of its cytoplasm on one side of the nucleus, 
as an osteoblast might also have. We can see mostly endoplasmic 
reticulum, mitochondria, and some people can see a bit of Golgi com- 
plex even at this low power. 
When we come to the osteocytes that are located deeper inside the 
trabeculae (fig. 105), we can now see Iarge, osmiophilic vesicles. The 
size of the lacuna is also increased. Finally, the largest of these osteo- 
cytes, which we find in confluent lacunae in the center of the trabeculae, 
contain a larger number of these osmiophilic vesicles in their cytoplasm. 
250 Biology of Hard Tissue 
FIGURE 105. A centrally located osteocyte from the same specimen as in figure 104. 
The lacuna is wide and apparently confluent with an adjacent one. Vesicles containing 
osmiophilic material (lysosomes?) are prominent. 
Some people say I should call them “lysosome-like” because I do not 
know whether or not they are lysosomes; they look like lysosomes. 
If we give parathyroid hormone to some of these chick embryos, 
putting PTE in the yolk, 2 units per gram for a chick of 7 grams in 
weight, more or less, for 24 hours, this is what we see (fig. 106). The 
osteocytes near the surface apparently mature very rapidly. Now the 
endoplasmic reticulum has become enlarged, and there are cisternae, 
such as described by Baud (ref. 173). The osmiophilic vesicles 
which hardly exist in the young osteocyte become fairly numerous 
after parathyroid hormone, and we even begin to see a structure like 
this, which some electron microscopists tell me is an autophagic body. 
This apparently is related to cell digestion from enzymes which issue 
from some of the osmiophilic vesicles. 
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FIGURE 106. Peripheral osteocyte from an 1 I-day chick embryo treated with PTE. 
Enlarged cisternae and numerous pinocytic vesicles are visible; more numerous osmio- 
philic vesicles are also present; some appear to have been released into the lacuna. 
So it is apparent that parathyroid hormone has increased the maturity 
of the cells, and has increased-as part of the maturity of the cells-the 
production of the osmiophilic vesicles which might be related to the 
production of protease. If this goes on for a time, the whole cell is 
destroyed, and we are left with an empty lacuna. 
NICHOLS: I would like to say something about fluoride. I have one 
more figure about another osteoporotic patient. 
We need to learn more about fluoride and its effects, because it is 
possible that we might learn how to treat osteoporosis even though we 
do not know what it is. Figure 107 shows roentgenographs of the 
lu'mbar spine and pelvis of a woman who came to me because she had 
developed acute pain in her back one day when she jammed on the 
brakes of her car. The picture on the left was made shortly after this 
episode when she was experiencing considerable pain from a crushed 
vertebra, and had obvious osteoporosis. One year later, she had the 
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FIGURE 107. Roentgenographs of lumbar spine and pelvis of a 53-year-old female with 
osteoporosis (left) and after fluoride treatment (right). 
picture on the right, which shows considerable thickening of the tra- 
beculae in her vertebra and pelvis. 
The woman was 53 years old. The clinical data which were found 
at that time are shown in the top half of table XXII. Serum calcium 
concentration was 4.6 mEq/l; alkaline phosphatase was normal, and 
urinary hydroxyproline excretion, which may or may not be an index 
of the rate at which collagen is destroyed in the body, was actually 
lower than normal of 28 milligrams for 24 hours. Metabolic studies 
of her bone biopsy showed normal lactate production and incorporation 
of glucose into collagen and cells. Proline incorporation into collagen 
was normal, but cell labeling was a little high and O2 uptake was just 
above the normal range as we have defined it. 
She was started at this point on 100 milligrams of sodium fluoride 
per day. About 5 months later she was completely symptom free and 
she has never had any pain since, nor does she have any evidence of 
any new crushed vertebra at this point. It took about 10 months for 
her to develop any roentgenographic change that we could recognize. 
When we did we biopsied her again. 
Serum calcium and so forth 
were normal. She did, however, show elevations of serum alkaline 
phosphatase activity and urinary hydroxyproline excretion. Bone 
metabolic data showed the same O2 uptake but reduction in lactate 
production. The striking changes are in the measurements which re- 
This was 1 1  months after the first one. 
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TABLE XXII 
SKELETAL METABOLIC CHANGES IN IATROGENIC FLUOROSIS 
[Female - Age 53 J 
I 
July 1964 
osteoporosis I Clinical data 
Serum Ca, mEq/l ............................. 
Serum F, mmoles/l ........................... 
Alkaline phosphatase, B-L units.. ....... 
Urine hydroxyproline, mgl24 hr. ......... 
Bone metabolic data per mg DNA: 
Oxygen uptake, pmoles .............. 
Lactate production, pmoles.. ........ 
Glucose incorporation, mp moles: 
Cells.. ................. 
Collagen.. .......................... 
Cells.. ............................... 
Collagen.. .......................... 
Proline incorporation, mpmoles: 
4.6 
1.3 
1.2 
15 
0.92 
1.17 
551 
4.60 
66.0 
0.19 
June 1965 
osteoporosis 
+fluorosis 
4.9 
1.2 
2.4 
40 
0.91 
0.72 
90 1 
20.7 
64.1 
0.79 
253 
Normal 
4.5-5.2 
1.0-1.5 
0.5-2.2 
24 k 4.9 
0.47k 0.22 
0.792 0.29 
320 2170.0 
4.00k 0.92 
23.4 k 7.84 
0.24k 0.09 
late to matrix biosynthesis. Glucose incorporation is now three times 
the normal value. The ratio of glucose to collagen is five times normal 
and the incorporation of proline label into collagen and cells is simi- 
larly increased. In other words, these data show that the roentgeno- 
graphic changes we call fluorosis are clearly reflected by increased 
bone-cell metabolism - especially in the area of bone collagen synthesis. 
This is important because it indicates that one can do something 
aboui this disease. One can substitute another disease for the one 
which is troubling the patient, a disease which is, relatively speaking, 
asymptomatic. 
The question that we do not know the answer to as yet is, “What 
happens when fluoride is stopped?” This patient has been off fluoride 
now for 4 months. Her alkaline phosphatase is back down to the nor- 
mal range, but whether this means that she is going to revert to her 
previous osteoporotic state I do not know. Time will have to supply 
the answer. She is, by the way, our one patient who has agreed to 
have a third biopsy. 
HOWELL: Is that not a calcified paravertebral ligament on this 
patient’s spine? 
NICHOLS: Yes. 
COPP: €s there any relationship between heparin-induced osteo- 
porosis and the fluoride type, and vice versa? 
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NICHOLS: There appears to be, in fluorosis, a stimulation of the 
biosynthetic machinery to make more matrix. What we do not know 
is whether there is a simultaneous specific inhibition of the biosyn- 
thesis of collagenase or other catheptic enzymes. This remains to be 
looked into. Unfortunately, we do not have an alalysis of collageno- 
lytic activity prior to sodium fluoride in this woman. 
The cause of the stimulation of matrix synthesis is not known either. 
In animals we have some observations which show that one can repro- 
duce this biosynthetic stimulation. Dr. Peck showed data last spring 
indicating that collagen synthesis is inhibited by fluoride, and we have 
had the same experience at certain dose levels. On the other hand, if 
the animal lives long enough, the corner seems to be turned and a rela- 
tive stimulation seems to begin. Dr. Peck, do you have a comment? 
PECK: We were giving large doses of fluoride in drinking water to 
weanling rats, and the situations are obviously not quite comparable 
(ref. 153). Significant inhibition< resulted, which was dose related. 
Our greatest effects occurred about 50 ppm for about 2 weeks to 1 
month in a weanling rat. That is really a lot of fluoride. 
URIST: Dr. Nichols, you have done a beautiful job. We will now 
adjourn. 
